Brief: Annji Pharma Entered Into An Exclusive License Agreement With Avenue Therapeutics

Avenue Therapeutics

10/03/2023 11:30

March 10 (Reuters) - Avenue Therapeutics Inc  ATXI.O :
    * ANNJI PHARMACEUTICAL - ENTERED INTO AN EXCLUSIVE LICENSE
AGREEMENT WITH AVENUE THERAPEUTICS INC
    * ANNJI PHARMACEUTICAL - LICENSE AGREEMENT WITH AVENUE FOR
DEVELOPMENT, COMMERCIALIZATION OF AJ201 IN U.S., CANADA, EU,
GREAT BRITAIN, ISRAEL FOR SPINAL & BULBAR MUSCULAR ATROPHY
    * ANNJI PHARMACEUTICAL - UNDER TERMS OF LICENSE AGREEMENT,
ANNJI
WILL RECEIVE UPFRONT PAYMENTS OF $3 MILLION
    * ANNJI PHARMACEUTICAL - ENTITLED TO RECEIVE FUTURE
MILESTONE
PAYMENTS AMOUNTING UP TO 250 MILLION USD, & UP TO 2-DIGIT
PERCENTAGE ROYALTY OF THE NET SALES
    * ANNJI PHARMACEUTICAL - WILL RETAIN MANUFACTURING RIGHT TO
PROVIDE CLINICAL & COMMERCIAL SUPPLY OF AJ201 TO AVENUE UNDER
AGREED SALE PRICE

Source text for Eikon:  ID: 
Further company coverage:  ATXI.O 

 ((Reuters.Briefs@thomsonreuters.com;))